1263941-29-2

Upstream product

• 1609173-80-9 C₁₆H₂₂N₂O₂ 
• 6804-53-1 4-(4-trifluoromethyl-phenyl)-1⁽²⁾H-pyrazol-3-ylamine 
• 1263941-25-8 N-(1-phenyl-2-(3-(4-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidin-7-yl)propan-2-yl)acetamide 
• 1264296-51-6 1-phenyl-2-(3-(4-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidin-7-yl)propan-2-amine 
• 1264296-50-5 tert-butyl 1-phenyl-2-(3-(4-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidin-7-yl)propan-2-ylcarbamate 
• 1264296-49-2 tert-butyl 5-(diethylamino)-2-methyl-3-oxo-1-phenylpent-4-en-2-ylcarbamate 
• 1264296-48-1 tert-butyl 2-methyl-3-oxo-1-phenylpent-4-yn-2-ylcarbamate 
• 1264296-47-0 tert-butyl 3-hydroxy-2-methyl-1-phenylpent-4-yn-2-ylcarbamate 

Relevant academic research and scientific papers

Discovery of structurally novel, potent and orally efficacious GPR119 agonists

Screening hit 5 was identified in a biochemical screen for GPR119 agonists. Compound 5 was structurally novel, displayed modest biochemical activity and no oral exposure, but was structurally distinct from typical GPR119 agonist scaffolds. Systematic opti

COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY

The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119.